By focusing on new targets, novel MOA and new modalities ... Established platforms such as the XDC platform, peptide technology platform, PROTAC/molecular glue platform, and antibody/large molecule ...

By focusing on new targets, novel MOA and new modalities ... peptide technology platform, PROTAC/molecular glue platform, and antibody/large molecule R&D technology platform.

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...

The deal – which includes an upfront payment of $49 million – will see the two companies collaborate on the discovery of molecular glue degraders "for multiple targets in several disease areas ...

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...

Net profit recorded RMB222.0 million, a significant turnaround from a year ago Adjusted Non-IFRS net profit recorded RMB314.6 million, a YOY increase of nearly 50.6%. In addition, the Group's ...

A near-infrared optogenetic system was developed for the controlled expression of therapeutics in engineered oncolytic bacteria, demonstrating significant anti-tumor efficacy in multiple tumor ...

MoA All America Fund earns an Average Process Pillar rating. The main driver of the rating is its parent firm's impressive long-term risk-adjusted performance, as shown by the firm's average 10 ...

CMD-GEN is a structure-based framework for selective inhibitor design, combining coarsegrained pharmacophore sampling with generative models to optimize molecular stability, druglikeness ...